중동 및 아프리카 점성보충제 시장, 출처(동물성 및 비동물성), 연령대(노인 및 성인), 주사(단일 주사, 3회 주사 및 5회 주사), 분자량(중간 분자량, 저분자량 및 고분자량), 최종 사용자(병원, 정형외과 병원, 외래 진료소 및 기타), 유통 채널(직접 입찰 및 소매 판매) - 업계 동향 및 2029년까지의 예측.
중동 및 아프리카 점성 보충 시장 분석 및 통찰력
중동 및 아프리카 점성 보충 시장은 2022년에서 2029년의 예측 기간 동안 성장할 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 6.2%의 CAGR로 성장하고 있다고 분석합니다. 의료 분야에서 점성 보충 치료의 기술적 발전이 증가함에 따라 예측 기간 동안 중동 및 아프리카 점성 보충 시장이 성장하는 또 다른 요인이 되었습니다.
그러나 일시적 주사, 부위 통증, 부기, 열, 발적 손실과 같은 치료 및 부작용과 관련된 높은 비용은 시장 성장을 제한할 것입니다. 주요 시장 참여자의 파트너십 및 인수와 같은 전략적 제휴 채택은 중동 및 아프리카 점성 보충 시장 성장의 기회로 작용합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 |
|
양적 단위 |
매출(USD) 백만 단위 볼륨, 가격(USD) |
|
다루는 세그먼트 |
출처별(동물성 및 비동물성), 연령대별(노인 및 성인), 주사(단일 주사, 3회 주사 및 5회 주사), 분자량별(중간 분자량, 저분자량 및 고분자량), 최종 사용자별(병원, 정형외과, 외래 진료소 및 기타), 유통 채널별(직접 입찰 및 소매 판매) |
|
적용 국가 |
사우디 아라비아, UAE, 이집트, 이스라엘, 남아프리카, 쿠웨이트 및 기타 중동 및 아프리카 |
|
시장 참여자 포함 |
중동 및 아프리카 점성 보충 시장에서 활동하는 주요 업체로는 Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici SPA, Ferring BV, sanofi-aventis US LLC, Zimmer Biomet, OrthogenRx, Inc.(자회사) 등이 있습니다. AVNS), APTISSEN, Johnson & Johnson Services, Inc., LG 화학, Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore(Landec Corporation의 자회사), VIRCHOW BIOTECH, Zuventus HealthCare Ltd.(Emcure Pharmaceuticals의 자회사) 등이 있습니다. |
시장 정의
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Dynamics
Drivers
- Rising geriatric population
With this increasing age comes a reciprocal increase in the elderly patients admitted to the hospitals due to fatal traumatic injuries. The rising prevalence of knee osteoarthritis diseases leads to increasing demand for diagnosis and treatment. With the growing population, the pressure on the healthcare system is rising. The increasing need for the proper treatment proportionally surges the demand for care, services, and technologies for the prevention and treatment of knee osteoarthritis conditions such as sarcopenia, osteoporosis, osteopenia, and other complications. The elderly population is more prone to these conditions leading to fragile bones and joints. In such patients, viscosupplementation is used in the procedure to provide them with immediate and efficient benefits associated with their bodies.
With this increasing age and rising prevalence of osteoarthritis, the demand for early diagnosis of the diseases is also increasing. Therefore, the demand for viscosupplementation is rising for the treatment in the healthcare system across the globe.
- Increasing risk of osteoporosis and osteoarthritis
Osteoporosis is a disease of bone that progresses due to less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength. It is more observed in women as compared to men. The post-menstrual women often get bone fractures due to osteoporosis as the disease is silent and typically shows no symptoms. Mostly elderly people are more prone to osteoporosis. Osteoarthritis is a joint disease or an inflammation of the joints and surrounding tissues. The mobility of a person is affected when such conditions occur.
The silent diseases such as osteoporosis and osteoarthritis show no symptoms and weaken the person's bone, leading to major fatalities such as spine malformation, fracture, sudden fall, or breakage of bone, among others. Thus, the increased risks of these conditions directly enhance the demand for viscosupplementation required to treat the malformations due to such conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive the growth of the Middle East & Africa viscosupplementation market.
Restraint
- Lack of technical expertise
Finding, attracting, and hiring talent is also the first step in building a professional bench of engineers and technicians. Even in the best of circumstances, this procedure can be challenging. Manufacturing existing workforce is rapidly aging and retiring. In the medical industry, there is a scarcity of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and undergraduate/post-graduate skills (engineers) remains strong in manufacturing, the number of people with the necessary skills is approaching a trickle. Only trained professionals should perform viscosupplementation, but this number is much less across the globe as these procedures are complex.
However, putting together a good additive manufacturing (AM) workforce entails more than just finding and recruiting qualified candidates. Employees must be qualified to remain current and maintain required skills as technology shift and grow. Even with their STEM-focused education, newly minted engineers would certainly need on-the-job training in AM techniques, which is one of the major challenges of recruiting and hiring them. Indeed, many undergraduate engineering programs provide little in the way of AM-specific education, and as a result, many graduates can lack the AM skills that employers seek.
Thus, the lack of technical expertise may act as a restraint for the market's growth.
Opportunity
- Safety and effectiveness of intra-articular hyaluronic acid (IAHA)
There are several types of hyaluronic acid injections, also called viscosupplementation, which are used for knee osteoarthritis. They are made from either rooster or chicken combs or are derived from bacteria and are injected directly into the joint. Intra-articular hyaluronic acid is a US Food and Drug Administration-approved treatment for knee osteoarthritis (OA). Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic AEs associated with IA corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions. IAHA is demonstrated to have a positive effect on pain and joint function. There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including a reduction in concomitant analgesia use and a delay in the need for total knee replacement surgery.
Challenge
- Stringent government policies for THE USE OF viscosupplementation
The commercialization of viscosupplementation across the globe by various key market players is facilitated by compliance with the regulatory frameworks established by many countries across the globe. The pre-market approval of various medical devices varies from one country to another. The U.S. Food, Drug, and Cosmetic Act ("FD&C Act") classify medical devices in the U.S. The European Union (EU) regulates medical devices in Europe. However, the rapid development of privacy policies and regulations are being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia.
The viscosupplementation is regulated by a structure of laws, rules, and regulations that are extensive and complex to safeguard them from use in any potential harmful treatment.
The viscosupplementation act as a replacement for the damaged, injured, or infected body parts in cases of osteoarthritis conditions or sports accidents among patients, along with maintaining the patient's demand for good body movement. However, any misguidance will affect the patient's safety and body structure.
Therefore, the stringent rules & regulations for the use of viscosupplementation may act as a challenge to the growth of the market.
Post COVID-19 Impact on the Middle East & Africa Viscosupplementation Market
COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to impact the Middle East & Africa viscosupplementation market greatly.
Middle East & Africa Viscosupplementation Market Scope and Market Size
Middle East & Africa viscosupplementation market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.
BY SOURCE
- ANIMAL ORIGIN
- NON-ANIMAL ORIGIN
On the basis of source, the viscosupplementation market is segmented into the animal origin and non-animal origin.
BY MOLECULAR WEIGHT
- HIGH MOLECULAR WEIGHT
- LOW MOLECULAR WEIGHT
- INTERMEDIATE MOLECULAR WEIGHT
On the basis of molecular weight, the viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.
BY INJECTION
- SINGLE INJECTION
- THREE INJECTION
- FIVE INJECTION
On the basis of injection, the viscosupplementation market is segmented into single injection, three injections, and five injections.
BY AGE GROUP
- ADULTS
- GERIATRICS
On the basis of age group, the viscosupplementation market is segmented into geriatric and adults.
END-USER
- HOSPITALS
- ORTHOPEDIC CLINIC
- HOME HEALTHCARE
- OTHERS
On the basis of end-user, the viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others.
BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
On the basis of distribution channel, the viscosupplementation market is segmented into direct tender and retail sales.
Viscosupplementation Market Country Level Analysis
The viscosupplementation market is analyzed, and market size information is provided by source, age group, molecular weight, injection, end user, and distribution channel.
The countries covered in the Middle East & Africa viscosupplementation market report are the Saudi Arabia, U.A.E, Egypt, Israel, South Africa, Kuwait, and rest of the Middle East and Africa.
In 2022, South Africa is dominating due to the rise in the incidence of obesity and osteoarthritis. South Africa is expected to grow due to technological advancements in drug treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.
Middle East & Africa viscosupplementation market also provides you with a detailed market analysis for every country growth in the healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, the impact of regulatory scenarios, and trending parameters regarding the Middle East & Africa viscosupplementation market.
Competitive Landscape and Middle East & Africa Viscosupplementation Market Share Analysis
Middle East & Africa viscosupplementation market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to viscosupplementation treatments.
The major companies which are dealing in the viscosupplementation market are Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx, Inc. (a subsidiary of AVNS), APTISSEN, Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals), among others
Strategic alliances like mergers, acquisitions, and agreements by the key market players are further expected to accelerate the growth of viscosupplementation treatments.
For instance,
- In May, 2022, Fidia Farmaceutici S.p.A. harnesses the regenerative power of hyaluronic acid with its innovative portfolio launched in Spain
Fidia Farmaceutici S.p.A. presented its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. The company has launched its complete Hyal System and Hy-Tissue portfolio in Spain. This has helped the company to showcase its research for hyaluronic acid
- In June 2022, Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with medicine achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, a dactylitis,b spinal pain, and disease severityc endpoints – irrespective of baseline characteristics. This has helped the company to showcase its progress
- LG화학은 2021년 11월 차세대 골관절염 치료제 개발을 위한 임상개발을 시작했습니다. LG화학은 골관절염 치료제 신약 후보물질인 LG00034053의 긍정적인 전임상 결과를 바탕으로 한국식품의약품안전처로부터 1b/2상 임상 시험을 승인받았다고 발표했습니다. LG화학은 1상과 2상을 연결하는 임상 시험을 설계하여 신약 개발을 가속화할 계획입니다.
이는 회사가 골관절염 치료를 위한 새로운 약물을 개발하는 데 도움이 되었습니다.
- 2020년 11월, Viatris Inc.는 Mylan NV와 Pfizer의 Upjohn 사업을 성공적으로 통합했습니다. 이 두 개의 상호 보완적인 기존 회사를 통합함으로써 Viatris는 165개 이상의 국가와 영토에서 환자에게 고품질 의약품을 제공하기 위한 입증된 규제, 의료 및 중동 및 아프리카 상업 역량과 함께 과학, 제조 및 유통 전문 지식을 갖추고 있습니다. 이를 통해 회사는 사업을 확장할 수 있었습니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략을 통해 중동 및 아프리카 점성 보충 시장에서 회사의 입지를 강화하고 있으며, 이는 조직의 수익 성장에도 도움이 됩니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, MEA 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
7 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET
8 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: REGULATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING GERIATRIC POPULATION
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS
9.2 RESTRAINTS
9.2.1 LACK OF TECHNICAL EXPERTISE
9.2.2 PRODUCT RECALL PROCEDURES
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION
9.3 OPPORTUNITIES
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA)
9.3.2 RISING HEALTHCARE INFRASTRUCTURE
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT
9.4 CHALLENGES
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION
10 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NON-ANIMAL ORIGIN
10.2.1 ORTHOVISC
10.2.2 EUFLEXXA
10.2.3 MONOVISC
10.2.4 DUROLANE
10.2.5 GEL-ONE
10.2.6 SUPARTZ
10.2.7 GELSYN-3
10.2.8 CINGAL
10.2.9 SULPLASYN
10.2.10 VISCOSEAL
10.2.11 OSTEONIL
10.2.12 OTHERS
10.3 ANIMAL ORIGIN
10.3.1 HYLAN G-F 20
10.3.2 SYNVIC ONE
10.3.3 SYNVIC
10.3.4 OTHERS
10.3.5 HYALURONANS
10.3.6 HYALGAN
10.3.7 OTHERS
11 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT
11.1 OVERVIEW
11.2 INTERMEDIATE MOLECULAR WEIGHT
11.2.1 ORTHOVISC
11.2.2 EUFLEXXA
11.2.3 MONOVISC
11.2.4 DUROLANE
11.2.5 VISCOSEAL
11.2.6 OSTEONIL
11.2.7 OTHERS
11.3 LOW MOLECULAR WEIGHT
11.3.1 HYLAGAN
11.3.2 SUPARTZ
11.3.3 GELSYN-3
11.3.4 CINGAL
11.3.5 SULPLASYN
11.3.6 OTHERS
11.4 HIGH MOLECULAR WEIGHT
11.4.1 SYNVIC ONE
11.4.2 SYNVIC
11.4.3 OTHERS
12 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION
12.1 OVERVIEW
12.2 SINGLE INJECTION
12.3 THREE INJECTION
12.4 FIVE INJECTION
13 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
14 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 ORTHOPEDIC CLINICS
14.4 AMBULATORY CARE CENTERS
14.5 OTHERS
15 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.3 DIRECT TENDER
16 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 EGYPT
16.1.3 SAUDI ARABIA
16.1.4 U.A.E
16.1.5 ISRAEL
16.1.6 KUWAIT
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JOHNSON & JOHNSON SERVICES, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 BIOVENTUS
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 FERRING B.V.
19.3.1 COMPANY SNAPSHOT
19.3.2 COMPANY SHARE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 SANOFI-AVENTIS U.S. LLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 ZIMMER BIOMET
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 SEIKAGAKU CORPORATION
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ANIKA THERAPEUTICS, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 FIDIA FARMACEUTICI S.P.A
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 APTISSEN
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 IBSA INSTITUT BIOCHIMIQUE SA
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 LG CHEM.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS)
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 ORTOBRAND INTERNATIONAL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 TRB CHEMEDICA SA
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENTS
19.17 VIATRIS INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 VIRCHOW BIOTECH
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA NON-ANIMAL IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 5 MIDDLE EAST & AFRICA ANIMAL IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 9 MIDDLE EAST & AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 11 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA SINGLE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA THREE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA FIVE INJECTION IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ADULT IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA GERIATRIC IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA HOSPITALS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA ORTHOPEADIC CLINICS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA AMBULATORY CARE CENTERS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA RETAIL SALES IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN VISCOSUPPLEMENTATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 37 MIDDLE EAST AND AFRICA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 40 MIDDLE EAST AND AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 42 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 53 SOUTH AFRICA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 54 SOUTH AFRICA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 57 SOUTH AFRICA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 58 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 EGYPT VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 67 EGYPT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 68 EGYPT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 69 EGYPT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 70 EGYPT ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 EGYPT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 72 EGYPT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 73 EGYPT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 74 EGYPT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 75 EGYPT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 76 EGYPT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 77 EGYPT VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 78 EGYPT INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 79 EGYPT LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 80 EGYPT HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 81 EGYPT VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 82 EGYPT VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 83 EGYPT VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 EGYPT VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 86 SAUDI ARABIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 87 SAUDI ARABIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 88 SAUDI ARABIA NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 89 SAUDI ARABIA ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 SAUDI ARABIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 91 SAUDI ARABIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 92 SAUDI ARABIA HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 93 SAUDI ARABIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 94 SAUDI ARABIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 95 SAUDI ARABIA HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 96 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 97 SAUDI ARABIA INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 98 SAUDI ARABIA LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 99 SAUDI ARABIA HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 100 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 101 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 102 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 SAUDI ARABIA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 104 U.A.E VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 105 U.A.E NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 106 U.A.E NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 107 U.A.E NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 108 U.A.E ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 U.A.E HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 110 U.A.E HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 111 U.A.E HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 112 U.A.E HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 113 U.A.E HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 114 U.A.E HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 115 U.A.E VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 116 U.A.E INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 117 U.A.E LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 118 U.A.E HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 119 U.A.E VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 120 U.A.E VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 121 U.A.E VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 U.A.E VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 ISRAEL VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 124 ISRAEL NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 125 ISRAEL NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 126 ISRAEL NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 127 ISRAEL ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 ISRAEL HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 129 ISRAEL HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 130 ISRAEL HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 131 ISRAEL VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 132 ISRAEL INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 133 ISRAEL LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 134 ISRAEL HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 135 ISRAEL VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 136 ISRAEL VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 137 ISRAEL VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 138 ISRAEL VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 139 KUWAIT VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 140 KUWAIT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 141 KUWAIT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 142 KUWAIT NON-ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP,USD)
TABLE 143 KUWAIT ANIMAL ORIGIN IN VISCOSUPPLEMENTATION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 KUWAIT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 145 KUWAIT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 146 KUWAIT HYLAN G-F 20 IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 147 KUWAIT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 148 KUWAIT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (UNITS)
TABLE 149 KUWAIT HYALURONANS IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (ASP, USD)
TABLE 150 KUWAIT VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT, 2020-2029 (USD MILLION)
TABLE 151 KUWAIT INTERMEDIATE MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 152 KUWAIT LOW MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 153 KUWAIT HIGH MOLECULAR WEIGHT IN VISCOSUPPLEMENTATION MARKET, BY BRAND, 2020-2029 (USD MILLION)
TABLE 154 KUWAIT VISCOSUPPLEMENTATION MARKET, BY INJECTION, 2020-2029 (USD MILLION)
TABLE 155 KUWAIT VISCOSUPPLEMENTATION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 156 KUWAIT VISCOSUPPLEMENTATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 KUWAIT VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 REST OF MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET, BY SOURCE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 THE INCREASING DEMAND FOR NON-SURGICAL TREATMENTS FOR OSTEOARTHRITIS AND ADVANCEMENTS IN THE DEVELOPMENT OF HYALURONIC ACID-BASED THERAPIES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 NON-ANIMAL ORIGIN IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET
FIGURE 15 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, 2021
FIGURE 16 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, 2022-2029 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, 2021
FIGURE 20 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, 2022-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY MOLECULAR WEIGHT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, 2021
FIGURE 24 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, 2022-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY INJECTION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, 2021
FIGURE 28 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, 2021
FIGURE 32 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 36 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: SNAPSHOT (2021)
FIGURE 40 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2021)
FIGURE 41 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 MIDDLE EAST AND AFRICA VISCOSUPPLEMENTATION MARKET: BY SOURCE (2022-2029)
FIGURE 44 MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
